scholarly journals Therapeutic Effect of an Underwater Exercise Program for Patients with Peripheral Arterial Disease

2012 ◽  
Vol 24 (8) ◽  
pp. 687-690 ◽  
Author(s):  
Mohammad Al-Jazzar ◽  
Farag A Aly ◽  
Mohammed Al-Omran ◽  
Ahmad H Alghadir ◽  
Mohamed Y Berika
2021 ◽  
Vol 9 (10) ◽  
pp. 2428-2435
Author(s):  
Tingchao Zhang ◽  
Gaoyang Guo ◽  
Li Yang ◽  
Yunbing Wang

In this paper, an ultralow dose paclitaxel-coated balloon was developed. Benefiting from the unique design of the meglumine matrix and outer protective sheath, its therapeutic effect was comparable to those of commercial high-dose counterparts in the swine model.


2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Jialin Pan ◽  
Wenqin Liu ◽  
Ye Chen ◽  
Chi Zhang ◽  
Cong Lin

At present, the global prevalence of peripheral arterial disease is increasing year by year, and it has become a worldwide disease. Studies have shown that transplanting endothelial progenitor cells (EPCs) into ischemic tissues can improve the tissue ischemia, thereby having a therapeutic effect on peripheral arterial diseases. This indicates that EPCs play a therapeutic effect in peripheral arterial disease. Recent studies have shown that peptidylarginine deiminase (PAD) is involved in the regulation of epigenetics and its inhibitor Cl-amidine can improve endothelium-dependent vasodilation and significantly reduce the formation of arterial thrombosis. It can also play a role in hematopoietic stem cells that share the same origin with EPCs. Therefore, we speculate that PAD4 may also have an effect on EPCs through a similar mechanism, thereby participating in the damage and repair of peripheral arterial disease. Therefore, we first detected the expression of PAD4 in EPCs of peripheral arterial disease and detected changes in the number and function of endothelial progenitor cells in peripheral blood after injecting the PAD4 inhibitor Cl-amidine into mice. A mouse model of lower limb ischemia was established to explore the effect of PAD4 on the function of EPCs in peripheral arterial disease. The results show that PAD4 is highly expressed in peripheral arterial diseases and the PAD4 inhibitor Cl-amidine can increase the number of EPCs and can treat peripheral arterial diseases by improving the proliferation, migration, and vascularization of EPCs.


2019 ◽  
Vol 34 (1) ◽  
pp. 58-67
Author(s):  
Mohsin Ahmed ◽  
Abul Hasan Muhammed Bashar ◽  
Abdullah Al Gaddafi

The prevalence of peripheral artery disease (PAD) continues to increase worldwide. It is important to identify patients with PAD because of the increased risk of myocardial infarction, stroke, and cardiovascular death and impaired quality of life because of a profound limitation in exercise performance.Lower extremity PAD affects approximately 10% of population, with 30% to 40% of these patients presenting with claudication symptoms. Peripheral arterial disease is common, but the diagnosis frequently is overlooked because of subtle physical findings and lack of classic symptoms. Screening based on the ankle brachial index using doppler ultrasonography may be more useful than physical examination alone. Noninvasive modalities to locate lesions include duplex scanning, computed tomography angiogram, magnetic resonance angiography and invasive modalities peripheral angiogram is the gold standard. Major risk factors for peripheral arterial disease are cigarette smoking, diabetes mellitus, older age (older than 40 years), hypertension, hyperlipidemia, and hyperhomocystinemia. Intermittent claudication may be improved by risk-factor modification, exercise, and pharmacologic therapy. Based on available evidence, a supervised exercise program is the most effective treatment. Effective drug therapies for peripheral arterial disease include aspirin (with or without dipyridamole), clopidogrel, cilostazol, and pentoxifylline. By contrast, critical limb ischemia (CLI) is considered the most severe pattern of peripheral artery disease. It is defined by the presence of chronic ischemic rest pain, ulceration or gangrene attributable to the occlusion of peripheral arterial vessels. It is associated with a high risk of major amputation, cardiovascular events and death. The management of CLI should include an exercise program, guideline-based medical therapy to lower the cardiovascular risk. Most of the cases, revascularization is indicated to save limbs; an “endovascular first” approach and lastly surgical approach, if all measures were failed. The choice of the intervention is dependent on the anatomy of the stenotic or occlusive lesion; percutaneous interventions are appropriate when the lesion is focal and short but longer lesions must be treated with surgical revascularisation to achieve acceptable long-term outcome. Bangladesh Heart Journal 2019; 34(1) : 58-67


Author(s):  
Edita Jakubsevičienė ◽  
Karolina Mėlinytė ◽  
Raimondas Kubilius

The effectiveness of an individual six-month-long physical exercise program in improving health-related quality of life (HRQOL) is unclear. There is some evidence that an individual exercise program can be effective for this aim. The goal of this study was to compare an individual six-month-long physical exercise program for patients with PAD (Peripheral Arterial Disease) with a traditional exercise program and find the effect of these programs on HRQOL and PAD risk factors. The study included patients who underwent femoral–popliteal artery bypass grafting surgery. Patients were divided into three groups: patients participating in an individual six-month-long physical exercise program (group I), in the standard physical activity program (group II), and in a control group (group III), with no subjects participating in rehabilitation II. Results: group I patients had a significantly (p < 0.001) higher HRQOL at 6 months after their surgery compared with groups II and III. The HRQOL scores were significantly (p < 0.05) lower after surgery among older (≥ 65), overweight participants, as well as among patients with diabetes mellitus and cardiovascular diseases when comparing study results with patients without these risk factors.


2020 ◽  
Vol 43 (6) ◽  
pp. 537-545
Author(s):  
Arash Harzand ◽  
Alexander A. Vakili ◽  
Alaaeddin Alrohaibani ◽  
Smah M. Abdelhamid ◽  
Neil F. Gordon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document